The 31st National High School Manga Championship (Manga Koshien)
What is Manga Koshien?
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220408005170/en/
Flyer (Graphic: Business Wire)
It is a competition where teams of high school students compete on manga creations. This competition started in 1992 and celebrated its 30th anniversary last year. Since 2014, schools from overseas also started entering the competition, and we are seeing approximately 300 schools participating each year from Japan and abroad.
Teams of three to five students each work together to draw a one-page manga in accordance with a specified theme for the preliminaries. Those who manage to pass the preliminaries gather in Kochi during summer for the main round.
Teams in the main round (semifinals, revival round, finals) stand a chance to win the grand prize and other awards. This means prize money, drawing materials, and more! In addition, during the main round, talented students may even be scouted by major manga publishers and perhaps debut as professionals!
1. Preliminary Round Theme
- Space debris (Uchuu Gomi)
- ∞ Infinity (Mugen)
Draw and submit a one-page manga of either one of these themes.
Manga Koshien Website: https://mangaoukoku-tosa.jp/manga-koshien31/
2. Eligibility
- Japan and overseas senior high school students or similar (approximately 15 to 18 years of age)
- Only one team per school is allowed to participate.
3. Guidelines for the Preliminary Round Entries
- Entries should be submitted online at https://mangaoukoku-tosa.jp/manga-koshien31/
- The manga must be of B4 size (257mm x 364mm, in any orientation).
- The manga must be produced jointly by all students registered in the application form.
4. Timeline
(1) Preliminary Round (Online)
- Deadline: Tuesday, May 31st, 2022, 24:00 (JST)
- Judging: Tuesday, June 14th, 2022
- Chosen schools: 33 schools (30 from Japan, 3 from overseas)
(2) Main Round (Kochi Prefecture, Japan)
- Participants: 33 schools that passed the preliminary round
- Date: Saturday, 30th, and Sunday, 31st, July 2022
- Venue: Kochi Jibasan Center
- Participation fee: JPY 30,000 (per person)
*The participation fee will cover the participants’ air ticket, accommodation, etc.
*Travel arrangements will be made by the event organizer
5. Main Round Judges
- All 6 Preliminary Round Judges
-
Guest Judges
Fujimaki Tadatoshi (Famous works: Kuroko no Basuke, Robot x Laserbeam)
Yukimoto Shuuji (Famous works: Kemo Life, Shark Girl)
*For more details, please refer to the Implementation Outline at the following
URL: https://mangaoukoku-tosa.jp/manga-koshien31/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220408005170/en/
Contact information
In-charge: Yasuaki Okamatsu, Risa Matsumoto
Manga Kingdom Tosa Promotional Committee
(within the Manga Kingdom Tosa Office)
TEL: +81-(0)88-823-9711 FAX: +81-(0)88-823-9296
Email: 140201@ken.pref.kochi.lg.jp
Website: https://mangaoukoku-tosa.jp/manga-koshien31/
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release
Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom